InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 2 February 2024

BELINDA: This phase III trial is comparing an immunotherapy to standard of care treatment in adults who have been diagnosed with B-cell Non-Hodgkin Lymphoma and have failed prior immunochemotherapyTisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial

Clinical summary


Eligible patients will be randomised to receive the investigator's choice of optional platinum-based immunochemotherapy followed by (1) lymphodepleting chemotherapy (containing fludarabine with cyclophosphamide or bendamustine) and a single dose of Tisagenlecleucel OR (2, in responding patients only) high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT).


This trial is treating patients with B-Cell Non-Hodgkin Lymphoma


Blood Cancers Haematological





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Novartis Pharmaceuticals

Scientific Title

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial



  1. Histologically confirmed, aggressive B-cell NHL at relapse/progression or PR after front line therapy. Aggressive B-cell NHL is heretofore defined by the following list of subtypes (Swerdlow et al 2016):

    1. DLBCL, NOS,
    2. FL grade 3B,
    3. Primary mediastinal large B cell lymphoma (PMBCL),
    4. T cell rich/histiocyte rich large B cell lymphoma (T/HRBCL),
    5. DLBCL associated with chronic inflammation,
    6. Intravascular large B-cell lymphoma,
    7. ALK+ large B-cell lymphoma,
    8. B-cell lymphoma, unclassifiable, (with features intermediate between DLBCL and classical Hodgkin's Lymphoma (HL)),
    9. High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements,
    10. High-grade B-cell lymphoma, NOS
    11. HHV8+ DLBCL, NOS
    12. DLBCL transforming from follicular lymphoma
    13. DLBCL transforming from marginal zone lymphoma
    14. DLBCL, leg type
  2. Relapse or progression within 365 days from last dose of anti CD20 antibody and anthracycline containing first line immunochemotherapy or refractory (have not achieved a CR).
  3. Patient is considered eligible for autologous HSCT as per local investigator assessment. Note: Intention to transplant and type of high dose chemotherapy (HDCT) regimen will be documented at the time of study entry
  4. Disease that is both active on PET scan (defined as 5-Deauville scorepoint-scale of 4 or 5) and measurable on CT scan, defined as::

    1. Nodal lesions >15 mm in the long axis, regardless of the length of the short axis, and/or
    2. Extranodal lesions (outside lymph node or nodal mass, but including liver and spleen) >10 mm in long AND short axis
  5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  6. Adequate organ function:

    Renal function defined as:

    1. Serum creatinine of ≤1.5 x upper limit of normal (ULN), OR estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2

      Hepatic function defined as:

    2. Alanine Transaminase (ALT) and Aspartate Transiminase (AST) ≤ 5 × ULN
    3. Total bilirubin ≤ 1.5 x ULN with the exception of patients with Gilbert syndrome who may be included if their total bilirubin is ≤3.0 × ULN and direct bilirubin ≤1.5 × ULN

      Hematologic Function (regardless of transfusions) defined as:

    4. Absolute neutrophil count (ANC) >1000/mm3
    5. Absolute lymphocyte count (ALC) >300/mm3 OR Absolute number of CD3+ T cells >150/mm3 (only for patients with non-historical apheresis)
    6. Platelets ≥50000/mm3
    7. Hemoglobin >8.0 g/dl

      Adequate pulmonary function defined as:

    8. No or mild dyspnea (≤ Grade 1)
    9. Oxygen saturation measured by pulse oximetry > 90% on room air
    10. Forced expiratory volume in 1 s (FEV1) ≥ 50% and/or carbon monoxide diffusion test (DLCO) ≥50% of predicted level
  7. Must have a leukapheresis material of non-mobilized cells available for manufacturing.


  1. Prior treatment with anti-CD19 therapy, T cell therapy, or any prior gene therapy product
  2. Treatment with any systemic lymphoma-directed second line anticancer therapy prior to randomization. Only steroids and local irradiation are permitted for disease control
  3. Patients with active central nervous system (CNS) involvement by disease under study are excluded, except if the CNS involvement has been effectively treated and local treatment was >4 weeks before randomization
  4. Prior allogeneic HSCT
  5. Clinically significant active infection
  6. Any of the following cardiovascular conditions:

    • Unstable angina, myocardial infarction, coronary artery bypass graft (CABG), or stroke within 6 months prior to screening,
    • Left ventricle ejection fraction (LVEF) <45% as determined by echocardiogram (ECHO) or magnetic resonance angiography (MRA) or multigated acquisition (MUGA) at the screening assessment.
    • New York Heart Association (NYHA) functional class III or IV (Chavey et al 2001), within the past 12 months.
    • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II) and third degree AV block unless adequately controlled by pacemaker implantation.
    • Resting QTcF ≥450 msec (male) or ≥460 msec (female) at screening or inability to determine the QTcF interval
    • Risk factors for Torsades de Pointes (TdP), including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/ symptomatic bradycardia, or any of the following:
    • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome
    • Concomitant medication(s) with a "Known Risk of Torsades de Pointes" per that cannot be discontinued or replaced by safe alternative medication.
  7. Patients with active neurological autoimmune or inflammatory disorders (e.g., Guillain-Barré Syndrome (GBS), Amyotrophic Lateral Sclerosis (ALS)) and clinically significant active cerebrovascular disorders (e.g. cerebral edema, posterior reversible encephalopathy syndrome (PRES))

Other protocol-defined inclusion and exclusion criteria may apply.


  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.


  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.